# CCND2

Source: https://onco.cc/targets/ccnd2/  
OnCo record `ccnd2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.

## Summary

Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.

CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.69, genetic association 0.60, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cyclin D2; G1/S-specific cyclin-D2
- Tags: cancer-genes-wave
- Symbol: CCND2
- Class: tumor-suppressor
- Biology: Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Location: Nucleus; Cytoplasm; Nucleus membrane (UniProt). Locus 12p13.32 (HGNC).
- Where found: Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease; Colorectal cancer: Open Targets association 0.59 with colorectal cancer (MONDO_0005575); Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898); Non-small-cell lung cancer: CIViC evidence names this disease; Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL); Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 7 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1583: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1583
- UniProt P30279: https://www.uniprot.org/uniprotkb/P30279/entry
- NCBI Gene 894: https://www.ncbi.nlm.nih.gov/gene/894
- Ensembl ENSG00000118971: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118971

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ccnd2.json